Floatz logo

SX682

Adenoid Cystic Carcinoma

National Cancer Institute (NCI)Small moleculePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

10 Active assets in the Adenoid Cystic Carcinoma cohort.

Asset / SponsorPhaseRating
Cetuximab
Fox Chase Cancer Center
Phase 1/2B
Irinotecan
National Cancer Institute (NCI)
Phase 1/2B
VIPIVOTIDE TETRAXETAN
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 2CCC
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
Nivolumab
Instituto do Cancer do Estado de São Paulo
Phase 2CCC

View all 28 →

Same molecule, other indications

SX682 is also rated in:

metastatic prostate carcinomaDormant
B
Indicative ·
60 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
lung cancerDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →